

AVI BIOPHARMA INC  
Form 8-K  
November 14, 2003

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

### CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): November 14, 2003

## **AVI BioPharma, Inc.**

(Exact name of registrant as specified in its charter)

**Oregon**

(State or other jurisdiction of incorporation  
or organization)

**0-22613**

(Commission File Number)

**93-0797222**

(IRS Employer Identification Number)

**One S.W. Columbia, Suite 1105**

**Portland, OR 97258**

Edgar Filing: AVI BIOPHARMA INC - Form 8-K

(Address of principal executive offices)

**(503) 227-0554**

Registrant's telephone number, including area code

---

**Item 5. Other Events and Regulation FD Disclosure.**

The information set forth below pursuant to Item 12 shall also be deemed filed pursuant to Item 5.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated November 14, 2003 announcing the withdrawal of the offering under the prospectus supplement filed with the SEC on October 30, 2003.

**Item 12. Results of Operations and Financial Condition.**

AVI BioPharma, Inc. (the Company) issued a press release on November 14, 2003, before the opening of trading in its Common Stock on the Nasdaq National Market System. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

The Press Release announces the withdrawal of the offering under the prospectus supplement filed with the SEC on October 30, 2003.

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on November 14, 2003.

AVI BioPharma, Inc.

By: /s/ ALAN P. TIMMINS  
Alan P. Timmins  
*President and Chief Operating Officer*  
*(Principal Operating Officer)*